Lung Nodule Size Chart by Malignancy Risk (4mm to 30mm)

A scan report that says "8 mm pulmonary nodule" can mean anything from "ignore it" to "see a surgeon next week." The single most important number on the report is size, but the interpretation also depends on the nodule's density (solid versus subsolid), location, the patient's risk profile, and how it compares to prior scans. This guide turns those variables into a usable chart and explains the Lung-RADS framework that radiologists use to choose follow-up.

Lung Nodule Size and Cancer Risk: The Data

The two anchors are the Fleischner Society guidelines (most recent 2017 update) and Lung-RADS v2022 from the American College of Radiology. Both place malignancy risk on a steep size curve:

Nodule diameter	Approximate malignancy risk (solid)
<4 mm	<0.1%
4–6 mm	0.5–1%
6–8 mm	0.7–2.5%
8–15 mm	5–15%
15–30 mm	20–40%
>30 mm (mass)	>50%

Risk roughly doubles with every 5 mm of growth in the small-nodule range and quadruples once a nodule crosses 15 mm. These numbers shift with smoking history, age, family history, and emphysema burden — high-risk patients hit the same risk percentages at smaller sizes.

Lung-RADS Classification System Explained

Lung-RADS v2022 assigns every reported nodule a category 0–4X:

• Category 1 (Negative): No nodules, or nodules with benign features (calcified, fat). Continue annual LDCT.
• Category 2 (Benign appearance): Solid <6 mm, perifissural, or stable >2 years. Continue annual LDCT.
• Category 3 (Probably benign): Solid 6–8 mm at baseline or 4–6 mm new. Six-month LDCT follow-up.
• Category 4A (Suspicious): Solid 8–15 mm at baseline or 6–8 mm growing. Three-month LDCT or PET-CT.
• Category 4B (Very suspicious): Solid ≥15 mm or any solid endobronchial. PET-CT and biopsy strongly considered.
• Category 4X (Highly suspicious for malignancy): Specific features (spiculation, distortion, lymphadenopathy) regardless of size. Workup as cancer.

A clean LDCT report ending with "Lung-RADS 1" is the goal. "Lung-RADS 3" is the most common discordant call — most go on to be benign but require six-month surveillance for safety.

Solid vs Subsolid vs Ground-Glass: Why It Matters

Three textures, three different timelines:

• Solid nodules — the standard sized risk curve above applies
• Part-solid (subsolid with solid component) — highest cancer risk per mm; an 8 mm part-solid carries roughly the risk of a 15 mm pure solid
• Pure ground-glass (non-solid) — slowest to progress, often adenocarcinoma in situ; can be watched longer but rarely disappears completely

A 20 mm pure ground-glass nodule may have <10% malignancy risk in the short term but will need biopsy or surgery if it develops any solid component over time.

Sub-Centimeter Nodules (<10mm): Watch and Wait

The dominant clinical decision in this range is "annual versus six-month" rather than "biopsy now." Fleischner 2017 guidance for solid nodules in low-risk patients:

Diameter	Low-risk patient	High-risk patient
<6 mm	No routine follow-up	Optional 12-month CT
6–8 mm	6–12 month CT, then 18–24 months	6–12 month CT, then 18–24 months
8 mm	Consider 3-month CT, PET-CT, biopsy	Same with lower threshold

Subsolid sub-centimeter nodules generally get a 6-month re-image at baseline, then yearly out to 5 years.

10-30mm Nodules: Workup and Decisions

This is the size range where biopsy decisions are made. Standard tools:

• PET-CT — if SUVmax >2.5 in a solid nodule, biopsy is usually recommended. SUV is unreliable for pure ground-glass nodules and small subsolids.
• CT-guided percutaneous biopsy — for peripheral lesions; 90%+ diagnostic yield, 15–20% pneumothorax rate
• Bronchoscopy with EBUS — for central/perihilar lesions
• Surgical resection (VATS) — definitive for indeterminate cases >15 mm in surgical candidates

For tailored guidance on which procedure to pursue, our team can help.

>30mm Masses: Treat as Cancer Until Proven Otherwise

A pulmonary mass over 30 mm is roughly 50% likely to be malignant in average adults and substantially higher in smokers or those with weight loss/symptoms. Workup proceeds in parallel rather than serially: PET-CT for staging, biopsy for tissue diagnosis, brain MRI to rule out cerebral metastases, and a multidisciplinary tumor board review. Treatment planning often begins before final pathology is in hand.

Growth Rate as a Diagnostic Clue

Volume doubling time (VDT) — how long a nodule takes to double its volume — separates likely cancer from benign mimickers:

• VDT <100 days — usually inflammatory or infectious, not cancer
• VDT 100–400 days — high suspicion for cancer
• VDT >400 days — likely benign (or, in subsolid lesions, slow-growing in-situ adenocarcinoma)
• No measurable growth at 2 years (solid) — generally considered benign

Two LDCT studies separated by 3 months allow a meaningful VDT calculation. Hand calculation is unreliable; modern radiology software measures volume rather than diameter for accuracy.

International Patient Options for Nodule Workup

Self-pay options across major destinations:

Service	US (cash)	UK (private)	Mainland China
LDCT follow-up	$300–800	£200–400	¥1,200–2,500
PET-CT	$3,500–6,500	£1,500–2,500	¥6,500–9,000
CT-guided biopsy	$4,000–9,000	£2,500–4,500	¥6,000–12,000
VATS wedge resection	$25,000–50,000	£8,000–15,000	¥35,000–60,000

Centers commonly used by international patients in China include Sun Yat-sen Cancer Center (Guangzhou), Fudan Shanghai Cancer Center, PUMC Beijing, and HKU-Shenzhen. All operate modern multidisciplinary lung tumor boards.

Frequently Asked Questions

My report says "4 mm nodule, follow-up not required." Should I really ignore it?
For solid nodules under 6 mm in a low-risk patient, Fleischner and Lung-RADS both advise no routine follow-up. If you have heavy smoking history, family lung cancer, or symptoms, mention this to the radiologist — annual LDCT may still be sensible.

The nodule is the same size at one year. Am I safe?
Stability over 2 years for solid nodules and over 5 years for subsolid is the conventional definition of "benign." One year is reassuring but not yet conclusive.

How is volume different from diameter?
A 6 mm to 7 mm growth on diameter sounds small (17%) but represents a 59% volume increase — clinically meaningful. Modern software measures volume directly.

Can a PET-CT be done on a 5 mm nodule?
PET-CT is unreliable for nodules under 8 mm because the scanner's spatial resolution (~5 mm in modern systems) blurs uptake. Smaller nodules should usually be followed with serial LDCT instead.

What's the role of a liquid biopsy here?
For nodules in the 8–20 mm range, plasma-based circulating tumor DNA (ctDNA) panels can sometimes detect driver mutations early. Sensitivity remains low for sub-centimeter disease — useful as adjunct rather than replacement for tissue.

Is it worth flying for a second-opinion read of my CT?
Many international patients send their DICOM CT data to a second radiologist for review without travel. A formal second read at a top center costs roughly ¥800–2,000 in China and is usually returned within 3 business days.

Need Help Booking?

SinoCareLink can pre-book your LDCT, PET-CT, or biopsy at a top Chinese cancer center, coordinate pathology review, translate the radiology report into English, and arrange airport pickup. Contact us for a free consultation.